Jan Jaap van Lier

1.3k citations

38 papers · 1.0k indexed · h-index 18

Endocrinology, Diabetes and Metabolism top 5%
Molecular Biology
Cardiology and Cardiovascular Medicine top 10%
Surgery
Pharmacology top 5%

Co-authors: B. Oosterhuis Inga Bjørnsdottir Hans Helleberg J. H. G. Jonkman Milan Zdravkovic Monika Malm-Erjefält Annette Olsen Ad F. Roffel
Topics: Pharmacogenetics and Drug Metabolism (5 papers)Hormonal Regulation and Hypertension (5 papers)Atrial Fibrillation Management and Outcomes (3 papers)
Cited by: Endocrinology, Diabetes and Metabolism Pharmacology Cardiology and Cardiovascular Medicine
Journals: Blood Gastroenterology Journal of the American College of Cardiology
Partner nations: United States Germany Switzerland

In The Last Decade

Jan Jaap van Lier

38 papers receiving 963 citations

Peers

Countries citing papers authored by Jan Jaap van Lier

Since Specialization

Citations

This map shows the geographic impact of Jan Jaap van Lier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Jaap van Lier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Jaap van Lier more than expected).

Fields of papers citing papers by Jan Jaap van Lier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Jaap van Lier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Jaap van Lier. The network helps show where Jan Jaap van Lier may publish in the future.

Co-authorship network of co-authors of Jan Jaap van Lier

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Jaap van Lier. A scholar is included among the top collaborators of Jan Jaap van Lier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Jaap van Lier. Jan Jaap van Lier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor 2024 ·Clinical and Translational Science ·H. Shimizu,Michael A. Tortorici,(unknown),Kei Ogawa,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Jan Jaap van Lier,Stephen Djedjos,Brian Taylor Slingsby,David M. Rodman	11
2	Absorption, Distribution, Metabolism, and Excretion of [14C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies 2023 ·Drug Metabolism and Disposition ·(unknown),Kenneth Kulmatycki,Birk Poller,Andrea A. Romeo,Jan Jaap van Lier,(unknown),David Pearson	12
3	Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants 2021 ·Clinical and Translational Science ·(unknown),Martin C. Dyroff,(unknown),(unknown),(unknown),Andreas Port,(unknown),Jennifer Dong,Jan Jaap van Lier,William Tracewell,David Mitchell	11
4	Predictability of Elimination and Excretion of Small Molecules in Animalsand Humans, and its Impact on Dosimetry for human ADME Studies withRadiolabeled Drugs 2021 ·PubMed ·Ad F. Roffel,Jan Jaap van Lier,(unknown),(unknown)	1
5	Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers 2020 ·Investigational New Drugs ·Andreas Johne,(unknown),(unknown),Jan Jaap van Lier,(unknown),Michael Meyring	17
6	BMS-986278, A Lysophosphatidic Acid 1 (LPA ₁ ) Receptor Antagonist, in Healthy Participants: A Single/Multiple Ascending Dose (SAD/MAD) and Japanese MAD (JMAD) Phase 1 Study 2020 ·Giridhar Tirucherai,Dawei Yu,(unknown),George Klinger,Jan Jaap van Lier,Jörg Täubel,Edgar D. Charles	1
7	Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P₁ receptor modulator in healthy subjects 2020 ·Xenobiotica ·(unknown),Jan Jaap van Lier,Stephen English,Hartmut Fischer,Mike Ufer,Jasper Dingemanse	4
8	Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite 2020 ·Drug Metabolism and Disposition ·Ulrike Glaenzel,Yi Jin,(unknown),Kirsten Schroer,(unknown),Ulrike Pfaar,Jan Jaap van Lier,(unknown),Axel Meißner,Gian Camenisch,Sylvia Zhao	31
9	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species 2017 ·European Journal of Pharmaceutical Sciences ·Lene Jensen,Hans Helleberg,Ad F. Roffel,Jan Jaap van Lier,Inga Bjørnsdottir,Palle J. Pedersen,Everton Rowe,Julie Derving Karsbøl,Mette Lund Pedersen	124
10	Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers 2012 ·Drug Metabolism and Disposition ·(unknown),Jan Jaap van Lier,Katsuhiro Suzuki,Masanori Nagata,John Meijer,Walter Krauwinkel,Marloes Schaddelee,Mitsuhiro Sekiguchi,Aiji Miyashita,Takafumi Iwatsubo,Marcel van Gelderen,Takashi Usui	46
11	Antiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C Patients 2010 ·Hepatology ·Joep de Bruijne,Jean‐François Bergmann,H. W. Reesink,Christine J. Weegink,Richard Molenkamp,Janke Schinkel,Xiao Tong,Jing Li,Michelle Treitel,Eric Hughes,Jan Jaap van Lier,A.A. van Vliet,Harry L.A. Janssen,Robert J. de Knegt	24
12	Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase 2010 ·Drug Metabolism and Disposition ·Monika Malm-Erjefält,Inga Bjørnsdottir,(unknown),Hans Helleberg,(unknown),B. Oosterhuis,Jan Jaap van Lier,Milan Zdravkovic,Annette Olsen	153
13	Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone 2006 ·Clinical Pharmacokinetics ·Richard S. Geary,JoAnn D. Bradley,Tanya Watanabe,Younggil Kwon,Mark K. Wedel,Jan Jaap van Lier,(unknown)	39
14	Lack of effect of amisulpride on the pharmacokinetics and safety of lithium 2003 ·The International Journal of Neuropsychopharmacology ·(unknown),Eric Legangneux,Jan Jaap van Lier,A.A. van Vliet,Catherine Coulouvrat	9
15	Excretion and metabolism of desogestrel in healthy postmenopausal women 2001 ·The Journal of Steroid Biochemistry and Molecular Biology ·Carole Verhoeven,(unknown),(unknown),Jan Jaap van Lier,(unknown),Geny M. M. Groothuis,Ivonne M.C.M. Rietjens,R.M.E. Vos	9
16	Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge 2001 ·Journal of Cardiovascular Pharmacology ·Joachim Stangier,(unknown),(unknown),Thomas Meinicke,Jan Jaap van Lier,(unknown),Wim J. Tamminga,J. H. G. Jonkman	36
17	The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers 1998 ·British Journal of Clinical Pharmacology ·Emma J. Seaber,Richard Peck,Deborah A. Smith,(unknown),(unknown),Jan Jaap van Lier,(unknown),Johan Wemer,J. H. G. Jonkman	37
18	Pharmacokinetics of [14C]-labelled losigamone and enantiomers after oral administration to healthy subjects 1998 ·European Journal of Drug Metabolism and Pharmacokinetics ·P. A. M. Peeters,Jan Jaap van Lier,(unknown),B. Oosterhuis,Jaap Wieling,J. H. G. Jonkman,(unknown),A. Biber	9
19	The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints. 1997 ·PubMed ·Keith Wesnes,(unknown),Nanco Hefting,(unknown),(unknown),Emma Jenkins,(unknown),Julie C. Leonard,Orlando Petrini,Jan Jaap van Lier	49
20	Doubling Time And hCG Score For The Early Diagnosis Of Ectopic Pregnancy In Asymptomatic Women 1990 ·Acta Obstetricia Et Gynecologica Scandinavica ·Dick J. Tinga,Jan Jaap van Lier,(unknown)	11

About Jan Jaap van Lier

Jan Jaap van Lier is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Hematology, having authored 38 papers that have together received 1.0k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (5 papers), Hormonal Regulation and Hypertension (5 papers) and Atrial Fibrillation Management and Outcomes (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (340 citations), Pharmacology (130 citations) and Cardiology and Cardiovascular Medicine (162 citations). Jan Jaap van Lier has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include B. Oosterhuis, Inga Bjørnsdottir, Hans Helleberg, J. H. G. Jonkman, Milan Zdravkovic, Monika Malm-Erjefält, Annette Olsen, Ad F. Roffel, Julie Derving Karsbøl and Mette Lund Pedersen. Their work appears in journals such as Blood, Gastroenterology and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact